Open-Label Proof of Concept Study of LTX-315 in Basal Cell Carcinoma

• Status: Not yet recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This is a 3-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of LTX 315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC).

The study is expected to enroll approximately 66 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch biopsy).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Verrica Pharmaceuticals Inc.
• Collaborators: HeartcoR Solutions; Instat Clinical Research; Myonex; OncoBay Clinical

Criteria

Inclusion Criteria:

1. Adults ≥18 years of age

2. Clinically suspected BCC with at least 1 and up to 5 eligible lesion(s) suitable for biopsy and excision (see Section 5.4)

3. Willing to refrain from using nonapproved topical agents on, or within 2 cm of, the target BCC lesions and surrounding areas during the treatment period. Subjects should use topical agents that are gentle (eg, Aquaphor, CeraVe) and will not irritate the skin in these areas.

4. Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study

5. Written informed consent obtained, including consent for tissue to be examined by the central dermatopathologist and stored by the Sponsor or designee

6. Willing to undergo BCC surgical excision procedure of target and nontarget BCC lesions after study treatment

7. Willing to delay surgical excision of target and nontarget BCC lesions until the end of treatment (EOT) visit

8. Provides written consent to allow photographs of the target and nontarget BCC lesion to be used as part of the study data

9. Willing to practice a highly effective method of birth control while on study and until 4 weeks after the last treatment. Highly effective birth control includes sexual abstinence, vasectomy, bilateral tubal ligation/occlusion, or a condom with spermicide (men) combined with hormonal birth control or intrauterine device in women.

BCC Lesion Inclusion Criterion

1. The size of the lesion(s) must be ≥0.5 cm andpunch biopsy.

2. Histological diagnosis of nodular, micronodular, or superficial BCC, as confirmed by punch biopsy performed within 28 days of W1D1.

Exclusion Criteria:

1. Presence of known or suspected systemic cancer

2. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit

3. Treatment with systemic immunotherapy, immunomodulators or immunosuppressants within the 12 weeks prior to the screening period

4. Genetic or nevoid conditions (eg, Gorlin / basal cell nevus syndrome, xeroderma pigmentosa)

5. Clinically significant laboratory values, as assessed by the investigator, for the tests listed in the Schedule of Assessments, including:

1. serum creatinine >1.5× the upper limits of normal and

2. serum tryptase concentration >11.4 ng/mL

6. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the subject at undue risk, such as, but not limited to:

1. Uncontrolled infection or infection requiring antibiotics

2. Uncontrolled cardiac failure: Classification III or IV New York Heart Association

3. History of cerebrovascular or cardiac disorders, or subjects at particular risk of sequelae following a short hypotensive episode, including subjects with systolic BP <100 mmHg and/or diastolic BP <60 mmHg at screening or Day 1

4. Uncontrolled systemic or gastrointestinal inflammatory conditions

5. Known bone marrow dysplasia

6. History of positive tests for human immunodeficiency virus/acquired immunodeficiency syndrome or active hepatitis B or C

7. History of systemic autoimmune disease requiring anti-inflammatory or immunosuppressive therapy within 3 months prior to Day 1, with the following exceptions:

i. Subjects with a history of autoimmune thyroiditis are eligible provided the subject requires only thyroid hormone replacement therapy and disease has been stable for ≥1 year

ii. Subjects with well-controlled type I diabetes (in the opinion of the investigator) are eligible

h. Known mast cell activation syndrome, mastocytosis, or chronic idiopathic urticaria

7. Known sensitivity to any of the ingredients in the study medication

8. Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period

9. Evidence of current chronic alcohol or drug abuse

10. Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit

11. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study

12. Females who are pregnant or breastfeeding

BCC Lesion Exclusion Criteria

1. Recurrent or previously treated lesions

2. Lesions within 1 cm of the eyelids or lips, or on the hands, feet, ears, nose, and genitalia

3. Histological evidence of any other tumor in the biopsy specimen

4. Histological evidence of infiltrative, desmoplastic, sclerosing, or morpheaform BCC subtypes in the biopsy specimen

5. Medium- and high-risk basal cell carcinomas as defined by the National Comprehensive Cancer Network (NCCN) or Mohs Appropriate Use Criteria (ie, BCCs eligible for Mohs surgery).

TARGET LESION EXCLUSION ONLY:

6. For subjects with severe stasis dermatitis, target BCC lesions may not be on the lower extremities

7. Within 2 cm of the target BCC lesion(s):

1. Treatment with the following topical agents within the 12 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, corticosteroids, diclofenac, imiquimod, ingenol mebutate

2. Treatment with surgical excision, or curettage within the 2 weeks prior to the screening visit

3. Evidence of dermatological disease or confounding skin condition that may interfere with clinical evaluation (ie, psoriasis, atopic dermatitis, eczema, propensity to form keloids or hypertrophic scarring)

4. Use of topical immunomodulators during study

8. Within 5 cm of the target BCC lesion(s): history of any skin cancer, except for other currently identified target and nontarget BCC lesions

9. Target BCC lesion is in the area of prior resurfacing procedure with CO2 laser or any photodynamic and phototherapy treatment within the 3 months prior to the screening visit